Context Therapeutics Inc. Business Operations Contracts & Agreements
11 Contracts & Agreements
- Collaboration Agreements (2 contracts)
- Development Agreements (5)
- Indemnification Agreements (1)
- Services Agreements (1)
- Termination Agreements (1)
- Voting Agreements (1)
- Termination Agreement of the Clinical Trial Collaboration and Supply Agreement, dated March 21, 2023 between Context Therapeutics Inc. and Berlin-Chemie AG - Menarini Group (Filed With SEC on March 22, 2023)
- Development and Manufacturing Services Agreement, dated November (Filed With SEC on November 9, 2022)
- Amendment No. 3 to Process Development Agreement (Filed With SEC on November 9, 2022)
- Clinical Trial Collaboration and Supply Agreement, dated August 1, 2022, by and between Context Therapeutics Inc. and Berlin-Chemie AG - Menarini Group (Filed With SEC on August 11, 2022)
- Form of Indemnification Agreement between Context Therapeutics Inc. and its officers and directors (Filed With SEC on June 16, 2021)
- Amendment No. 2 to Process Development Agreement, dated June 3, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Filed With SEC on June 16, 2021)
- Form of Director Services Agreement (Filed With SEC on May 27, 2021)
- Amendment No. 1 to Process Development Agreement, dated April 21, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Filed With SEC on May 27, 2021)
- Process Development Agreement, dated March 6, 2020, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Filed With SEC on May 27, 2021)
- Research Collaboration and License Agreement, dated April 6, 2021, between Context Therapeutics LLC and Integral Molecular, Inc (Filed With SEC on May 27, 2021)
- Voting Agreement, dated December 22, 2020, among Context Therapeutics LLC and certain investors (Filed With SEC on May 27, 2021)
